fbpx

News in Gastric Cancer

News from around the world, curated by the Gastric Cancer Foundation.

A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancer

In an international phase 3 trial, researchers find S-1 (a contemporary oral fluoropyrimidine)/ cisplatin and 5-fluorouracil (5-FU)/cisplatin are similar in efficacy and safety in patients with advanced stomach cancer.

Read Source
Please join with us to fuel the next wave of progress.

Your support today will honor the memories of those we have lost and create much-needed hope for those who are bravely facing the disease today. Contributions are tax-deductible.
Please join with us to fuel the next wave of progress. Support our 2024 Fundraising Campaign.

Your support today will honor the memories of those we have lost and create much-needed hope for those who are bravely facing the disease today. Contributions are tax-deductible.

Together, we will defeat stomach cancer.

Together, we will defeat stomach cancer.

MORE INFODONATE
X